Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3/NF-κB pathway in mice - Wang, Q; Ou, Y; Hu, G; Wen, C; Yue, S; Chen, C (Br J Pharmacol, 2020)